no desc

Superior pain relief in Chronic Venous Disease patients undergoing after endovenous thermal ablation together with the Micronized Purified Flavonoid Fraction (MPFF).

The aim of the study was to evaluate the role of the Micronized Purified Flavonoid Fraction (MPFF) in the improvement of postoperative symptoms after endovenous thermal ablation (EVTA).

A prospective comparative study of 120 consecutive patients undergoing EVTA of the greater saphenous vein associated with phlebectomies was undertaken. Patients were grouped in those receiving the Micronized Purified Flavonoid Fraction (MPFF- 60 patients) agent 500 mg Bid 7 days pre-and 30 days post-operatively (MPFF group) and those in the control group (60 patients) who did not.

Demographics, intra-operative details, Clinical -Etiology- Anatomy- Pathophysiology (CEAP) clinical class, 10-cm Visual Analog Scale (VAS) for pain, Venous Clinical Severity Score (VCSS), and Chronic Venous Disease Quality-of-Life Questionnaire (CΙVIQ-20) were recorded. The primary outcome was the postoperative pain assessment using the VAS scale and CIVIQ pain score. Secondary outcomes included assessment of VCSS and CΙVIQ-20 scores.

There were no significant differences between the groups regarding demographics, clinical and procedural characteristics. Patients in MPFF group reported significantly lower VAS pain levels than control group at 7- (-3.6 ± 1.2 vs -2.7 ± 1.9, p < .0001) and 30- post-operative day (-4.9 ± 0.1 vs -4.2 ± 1, p < .0001). MPFF group also showed better outcome in terms of CIVIQ pain score at 7- (-3.7 ± 1.3 vs -3.5 ± 1.8,p = .008) and 30- post-operative day (-5.3. ± 1.1 vs -4.4 ± 1, p = .017). Both groups showed a significant improvement in VAS pain score (p = .047), global CIVIQ-20 (p = .009) and VCSS (p = .008) at 7- and 30-days post-operatively.

Administration of the Micronized Purified Flavonoid Fraction (MPFF) in patients undergoing EVTA associated with phlebectomies reduces pain by a small amount during the early postoperative period.

To know more : Click here

It can also interest you


February 4, 2022
Lifestyle and Risk Factors in Hemorrhoidal Disease
Venous disease


January 28, 2022
Making Use of Patient-Reported Outcome Measures (PROMs) for Haemorrhoidal Disea…
Venous disease


January 21, 2022
Assessment of venous leg symptoms in patients with hemorrhoidal disease (VEIN-H…
Venous disease
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.